Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | GSK3845097 |
Trade Name | |
Synonyms | GSK-3845097|GSK 3845097 |
Drug Descriptions |
GSK3845097 are autologous T lymphocytes engineered to express a dominant negative TGF-beta and a T-cell receptor targeting NY-ESO-1, which may lead to cytotoxic T-cell-mediated killing of NY-ESO-1-overexpressing tumor cells (J Clin Oncol 39, no. 15_suppl, abstract TPS2661). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C176041 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
GSK3845097 | GSK3845097 | 0 | 1 |